结构优化和生物评价Isoxazolo[5,4-d]pyrimidines作为选择性收费类受体 7 激动剂
Nika Strašek Benedik1, Ana Dolšak1, Urban Švajger1,2
1Faculty of Pharmacy, Department of Pharmaceutical Chemistry, University of Ljubljana, Aškerčeva 7, Ljubljana 1000, Slovenia.
ACS omega
|January 22, 2024
概括
研究人员使用新的异沙[5,4-d]胺基基架开发了新的托尔类受体7 (TLR7) 激活剂. 这些化合物在各种疾病中显示出免疫调节的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 药用化学 医学化学
背景情况:
- 收费类受体 (TLRs) 是关键的先天性免疫组件,参与炎症,传染病,自身免疫性疾病和癌症.
- 对于病毒感染,喘,过敏和癌症来说,TLR7激动剂显示出治疗的希望.
- 之前的研究已经确定了选择性TLR7激动剂,激发了寻找新的化学结构的动机.
研究的目的:
- 设计和合成一种新的TLR7激动剂化学型.
- 为了用一个异环替换quinazoline环的isoxazolo[5,4-d]pyrimidine.
- 为优化TLR7激动剂进行结构-活性关系 (SAR) 研究.
主要方法:
- 设计和合成新型的6-三甲基) 异醇[5,4-d] 胺-4-胺衍生物.
- 结构-活性关系 (SAR) 研究以确定强效和选择性TLR7激动剂.
- 对非细胞毒性和细胞因子诱导 (IL-1β,IL-12p70,IL-8,TNF-α) 的评估.
主要成果:
- 成功开发了一种基于6-三甲基 (trifluoromethyl) isoxazolo[5,4-d]pyrimidine-4-amine支架的新型TLR7激动剂类.
- 化合物显示出对TLR7激动因子的高选择性和低微分子强度.
- 化合物21a的EC50为7.8μM,无细胞毒性,并诱导显著的细胞因子分泌.
结论:
- 这种新型的isoxazolo[5,4-d]pyrimidine支架代表了一种有前途的新化学型,用于TLR7主动体的发展.
- 化合物21a因其强度,选择性和细胞因子诱导特性而显示出作为免疫调节治疗剂的潜力.
- 对这些TLR7激动剂的进一步研究可能会导致针对免疫相关疾病的新疗法.
相关概念视频
Dose-Response Relationship: Selectivity and Specificity
10.2K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
10.2K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.3K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.3K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
1.1K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.1K


